Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC-833: Results of a phase I/II multicenter study.

被引：0
|
作者：
List, AF
Karanes, C
Dorr, R
Spier, C
Grogan, T
Greer, J
Moore, J
Weinberger, J
Schiller, G
Dalton, W
Pearce, T
Litchman, M
机构：
[1] UNIV ARIZONA, TUCSON, AZ 85721 USA
[2] WAYNE STATE UNIV, DETROIT, MI 48202 USA
[3] VANDERBILT UNIV, NASHVILLE, TN 37240 USA
[4] DUKE UNIV, DURHAM, NC 27706 USA
[5] LOUISIANA STATE UNIV HLTH SCI CTR, SHREVEPORT, LA 71105 USA
[6] UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA
[7] SANDOZ, E HANOVER, NJ USA
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1156 / 1156
页数：1
相关论文
共 50 条
  • [1] A phase I/II study of SDZ PSC 833 (PSC) in combination with daunorubicin (D) and cytarabine in refractory acute myelogenous leukemia (AML).
    Liliemark, J
    Bjorkholm, M
    Uden, AM
    Hast, R
    Paul, C
    Simonsson, B
    Tidefelt, U
    Juliusson, G
    Hedenus, M
    Evensen, S
    Tangen, JM
    Sjo, M
    Nesthus, I
    Hestdal, K
    [J]. BLOOD, 1996, 88 (10) : 854 - 854
  • [2] Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
    Kornblau, SM
    Estey, E
    Madden, T
    Tron, HT
    Zhao, S
    Consoli, U
    Snell, V
    SanchezWilliams, G
    Kantarjian, H
    Keating, M
    Newman, RA
    Andreeff, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1796 - 1802
  • [3] Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (pts) ≥60 years (CALGB 9720).
    Baer, MR
    George, SL
    Dodge, RK
    Cooke, K
    Caligiuri, MA
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 1999, 94 (10) : 383A - 383A
  • [4] Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients (pts) with acute myeloid leukemia (AML) <60 years old:: Preliminary results of CALGB 9621.
    Kolitz, JE
    George, SL
    Hurd, D
    Hoke, E
    Dodge, RK
    Velez-Garcia, E
    Powell, BL
    Moore, J
    Caligiuri, MA
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 1999, 94 (10) : 384A - 384A
  • [5] A phase I study of mitoxantrone plus VP-16 with multidrug (MDR) blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia (R-AML)
    Kornblau, SM
    Estey, E
    Consoli, U
    Zhao, S
    Snell, V
    Newman, R
    Andreeff, M
    [J]. BLOOD, 1995, 86 (10) : 2044 - 2044
  • [6] Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia
    Dorr, R
    Karanes, C
    Spier, C
    Grogan, T
    Greer, J
    Moore, J
    Weinberger, B
    Schiller, G
    Pearce, T
    Litchman, M
    Dalton, W
    Roe, D
    List, AF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1589 - 1599
  • [7] Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia - Response
    Kopecky, KJ
    List, AF
    Appelbaum, FR
    [J]. BLOOD, 2002, 100 (01) : 366 - 367
  • [8] A phase I study of Tipifarnib and Bortezomib in the treatment of poor risk adult acute myeloid leukemia (AML)
    Papayannidis, Cristina
    Paolini, Stefania
    Lama, Barbara
    Ottaviani, Emanuela
    Salmi, Federica
    Iacobucci, Ilaria
    Curti, Antonio
    Cilloni, Daniela
    Parisi, Sarah
    Saglio, Giuseppe
    Fanin, Renato
    Morabito, Fortunato
    Pantaleo, Maria
    Lollini, Pier Luigi
    Baccarani, Michele
    Martinelli, Giovanni
    [J]. CANCER RESEARCH, 2009, 69
  • [9] Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
    Baer, MR
    George, SL
    Dodge, RK
    O'Loughlin, KL
    Minderman, H
    Caligiuri, MA
    Anastasi, J
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2002, 100 (04) : 1224 - 1232
  • [10] Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
    List, AF
    Kopecky, KJ
    Willman, CL
    Head, DR
    Persons, DL
    Slovak, ML
    Dorr, R
    Karanes, C
    Hynes, HE
    Doroshow, JH
    Shurafa, M
    Appelbaum, FR
    [J]. BLOOD, 2001, 98 (12) : 3212 - 3220
12345